Takeda Pharmaceutical Company Ltd

DelveInsight's report highlights a robust lupus nephritis pipeline with 30+ companies developing 35+ therapies, including key players like AstraZeneca and Novartis. Promising therapies like Anifrolumab and Ianalumab are in various clinical phases, with recent updates from companies like Adicet Bio and Kyverna Therapeutics. The report provides comprehensive insights into the pipeline, therapeutic assessments, and market dynamics.

Takeda, Novartis, and Gilead announced separate licensing agreements for medications targeting hematologic cancers, tumors, and Huntington disease. Takeda will develop elritercept for anemia in MDS and myelofibrosis, Novartis secured rights to PTC518 for Huntington disease, and Gilead partnered with Tubulis to develop an ADC for solid tumors.

T.C. has consulted/advised/spoken for ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Clinical Care Options, Daiichi Sankyo, Genentech, IDEOlogy Health, Medical Educator Consortium, Medscape, Merck, OncLive, oNKo-innate, PEAK Medicals, PeerView, Pfizer, Physicians’ Education Resource, RAPT Therapeutics, Regeneron, Targeted Oncology. W.N.W.Jr. has consulted/advised/spoken for Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Genentech/Roche, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi-Aventis, Takeda, United Medical.

Takeda enters exclusive licensing agreement with Keros Therapeutics to develop, manufacture, and commercialize elritercept, a late-stage activin inhibitor for treating anemia in hematologic cancers like myelodysplastic syndromes and myelofibrosis, outside of China, Hong Kong, and Macau.

DelveInsight's 'Graft versus host disease Pipeline Insight 2024' covers 60+ companies and 65+ pipeline drugs, including clinical and nonclinical stage products, with a focus on therapeutics assessment by product type, stage, route of administration, and molecule type. Key companies and promising therapies in development are highlighted.

Narcolepsy is a chronic neurological disorder affecting 1% globally, characterized by excessive daytime sleepiness, cataplexy, fragmented sleep, and sleep paralysis. Takeda developed TAK-861, an oral orexin agonist targeting the underlying cause of narcolepsy type 1 (NT1), aiming to restore orexin signaling and improve all symptoms, potentially offering a single-drug solution for patients.

Ponatinib plus chemotherapy received accelerated FDA approval for newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), with 30% achieving MRD-negative complete remission in the PhALLCON trial. Ponatinib, a tyrosine kinase inhibitor, demonstrated a 0.18 risk difference favoring its use over imatinib. The approval fills a gap in care for aggressive Ph+ ALL, with guidelines recommending dual therapy of chemotherapy plus TKI and considering allogeneic stem cell transplant. Ponatinib also showed efficacy in patients intolerant or unresponsive to other TKIs, though it carries a risk of thromboembolic events.

Niven R. Narain emphasizes that AI investments in drug development require robust data and validation. GEN's A-List highlights 10 AI-based drug discovery leaders, including BPGbio, which focuses on cancer energy generation. Other notable companies include Nvidia and Palantir Technologies, though not on the A-List. The list includes specifics on companies like Anima Biotech, Atomwise, and Nimbus Therapeutics, detailing their AI platforms and drug development progress.

Mirikizumab (Omvoh) showed improved outcomes in Crohn's disease patients with previous standard therapy failure, with 38% meeting composite endpoint of PRO clinical response at week 12 and endoscopic response at week 52 vs. 9% on placebo (P<0.0001). Mirikizumab also met primary endpoint of PRO clinical response at week 12 and CDAI clinical remission at week 52 in 45.4% vs. 19.6% on placebo (P<0.0001). The study highlights IL-23's role in Crohn's disease pathogenesis and suggests mirikizumab's favorable benefit-risk profile.